Genmab to Present Extensive Epcoritamab-bysp Development Program at 2024 ASH Meeting
Genmab A/S (Nasdaq: GMAB) has revealed that over 20 abstracts, including four oral presentations, will be presented at the 66th Annual Meeting and Exposition of the American Society of Hematology (ASH). These presentations will include new clinical data regarding epcoritamab, a T-cell engaging bispecific antibody, in treating various B-cell non-Hodgkin’s lymphoma (NHL) subtypes. The event will take place at the San Diego Convention Center, California, and online from December 7-10.
The development program for epcoritamab will be prominently featured at ASH 2023. The presentations include data on fixed-duration subcutaneous epcoritamab in patients with previously untreated diffuse large B-cell lymphoma (DLBCL), large B-cell lymphoma (LBCL), and relapsed/refractory (R/R) follicular lymphoma (FL). A separate presentation will focus on epcoritamab monotherapy in patients with R/R chronic lymphocytic leukemia (CLL). Important three-year efficacy and safety data for subcutaneous epcoritamab from the EPCORE® NHL-1 trial in patients with R/R DLBCL will also be highlighted.
Dr. Judith Klimovsky, Executive Vice President and Chief Development Officer of Genmab, expressed optimism about the potential of epcoritamab, noting that the data underscores its prospects as a core therapy for B-cell malignancies. This year has been pivotal for epcoritamab, with Genmab and its partner AbbVie committed to advancing its comprehensive development program to provide new therapeutic options for patients.
The abstracts accepted for presentation at ASH encompass both oral and poster presentations, with a variety of topics covered:
Oral Presentations:
- The efficacy of fixed-duration epcoritamab plus R2 in patients with R/R follicular lymphoma.
- High complete response rates in previously untreated DLBCL patients treated with fixed-duration epcoritamab plus R-CHOP.
- The first disclosure of fixed-duration epcoritamab monotherapy in older patients with untreated LBCL.
- Results from a study on epcoritamab monotherapy in patients with R/R chronic lymphocytic leukemia.
Poster Presentations:
- Exposure-response analyses supporting the optimal dosing schedule for epcoritamab in R/R follicular lymphoma.
- Epcoritamab combined with R-CHOP overcoming poor-risk features in high-risk LBCL.
- Initial results of fixed-duration epcoritamab combined with bendamustine and rituximab for first-line treatment of follicular lymphoma.
- Trends in all-cause mortality rates in patients with follicular lymphoma before and during the COVID-19 pandemic.
Epcoritamab, marketed as EPKINLY® in the U.S. and Japan and TEPKINLY® in the EU, is an IgG1-bispecific antibody developed using Genmab's DuoBody® technology. This technology harnesses cytotoxic T cells to provoke an immune response against target cells. Epcoritamab binds to CD3 on T cells and CD20 on B cells, leading to T-cell-mediated killing of CD20+ cells. It has received regulatory approval for certain lymphoma indications in various regions and is co-developed by Genmab and AbbVie. The companies are pursuing further international regulatory approvals for its use in relapsed/refractory (R/R) follicular lymphoma and additional R/R DLBCL indications.
Genmab and AbbVie are also investigating the use of epcoritamab as a monotherapy and in combination with other treatments across various hematologic malignancies. This includes ongoing Phase 3 trials evaluating epcoritamab as a monotherapy for R/R DLBCL, its combination with R-CHOP in newly diagnosed DLBCL patients, and its combination with rituximab and lenalidomide (R2) in both R/R FL and previously untreated FL patients.
Genmab is an international biotechnology company focused on developing innovative and differentiated antibody therapeutics. Established in 1999, it is headquartered in Copenhagen, Denmark, and operates worldwide. The company aims to transform the lives of people with cancer and other serious diseases through next-generation antibody medicines.
How to obtain the latest research advancements in the field of biopharmaceuticals?
In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!
